Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S1B-307
- Development stage
- Preclinical
- Lead developer
- S1 Biopharma, Inc.
- Modality
- Small Molecules
01
Overview
S1B-307 is a small molecule therapeutic candidate being developed by S1 Biopharma (also known as S1 Pharmaceuticals) for the treatment of various sexual health conditions. The drug is primarily targeted at Female Orgasmic Disorder (FOD) and Female Sexual Arousal Disorder (FSAD), but it is also being investigated for male indications, including delayed ejaculation and treatment-resistant erectile dysfunction. Developed via the FDA's 505(b)(2) regulatory pathway, S1B-307 is designed as a non-hormonal therapy that likely modulates neurobiological pathways involved in the sexual response cycle. As of recent pipeline updates, the program is in the IND-enabling and Phase 1 preparation stages.
Beyond the preview
Go deeper on S1B-307.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S1B-307.